Hologic stock holds near 52-week high as valuation and margins draw focus
Published on 09/08/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hologic stock (ISIN US4364401012) is trading close to its 52-week high, with the Nasdaq quote between USD 76.00 and USD 76.07 on September 8, 2026, implying a market capitalization of about USD 16.97 billion and a trailing price-to-earnings ratio of 31.67 according to MarketBeat.
Valuation and margins in the spotlight
As of September 8, 2026, Hologic, Inc. is valued at roughly USD 16.97 billion on the Nasdaq, based on a trailing twelve-month earnings per share of USD 2.40 and a price-to-earnings multiple of 31.67, according to data compiled by MarketBeat.
The same overview shows that Hologic generated net income of USD 565.70 million on annual sales of USD 4.10 billion in the most recently reported twelve-month period, corresponding to a net margin of 13.18 percent and a pretax margin of 16.08 percent, underlining that profitability remains solid in its medical technology niche.
Analyst targets signal limited upside
According to MarketBeat, twelve analysts currently cover Hologic stock with a consensus rating of Hold and an average price target of USD 79.13, framed by a high estimate of USD 90.00 and a low estimate of USD 76.00.
With the stock price around USD 76.07 on September 8, 2026, that average target implies potential upside of about 4.1 percent from the current level, indicating that, in aggregate, analysts see only modest room for further gains at this valuation.
Balance sheet strength supports strategy
The latest key figures compiled by MarketBeat show that Hologic operates with a debt-to-equity ratio of 0.48, a current ratio of 4.04 and a quick ratio of 3.32, signalling a relatively conservative balance sheet and ample short-term liquidity.
For investors, this combination of moderate leverage and strong liquidity metrics supports the company’s ability to keep funding research and development, bolt-on acquisitions and regulatory work in women’s health even if market conditions become more volatile.
Core product area in women’s health
Hologic focuses on medical technology for women’s health, including diagnostic products, imaging systems and surgical solutions, with a strong presence in breast and skeletal health as well as molecular diagnostics and gynecological procedures, according to MarketBeat.
The company’s portfolio spans digital and 3D mammography systems, bone densitometry equipment and molecular assays for infectious disease and oncology applications, and it serves hospitals, diagnostic laboratories and imaging centers in more than 100 countries, giving it a broad installed base for recurring revenue from consumables and services.
Hologic stock near recent highs
On Nasdaq, Hologic stock traded in a 52-week range between USD 51.90 and USD 76.07, with the recent quote around USD 76.07 placing the shares essentially at their 52-week high as of September 8, 2026, based on data from MarketBeat.
Against this backdrop, the combination of a near-peak trading range, a price-to-earnings ratio of 31.67 and a consensus Hold rating suggests that many investors are now weighing further upside potential primarily against execution on growth in diagnostics and surgical solutions rather than multiple expansion.
Hologic stock at a glance
- Company: Hologic, Inc.
- ISIN: US4364401012
- Ticker: HOLX
- Trading venue: Nasdaq
- Price (as of September 8, 2026): 76.07 USD
- Market capitalization: 16.97 billion USD (as of September 8, 2026)
- Sector / Industry: Healthcare / Medical technology and diagnostics
- Index membership: S&P 500
